Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | KDM6B | O15054 | 1/20 | 0.75 |
| ▸ | KDM5C | P41229 | 1/20 | 0.75 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.75 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.75 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.75 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.69 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.69 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | ENO1 | P06733 | 1/20 | 0.45 |
| ▸ | ECE1 | P42892 | 1/20 | 0.43 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8638420 | 0.89 | FOLH1 (0.63) | FOLH1KDM4EKDM6BKDM5CEGLN1 | |
| SCHEMBL240068 | 0.87 | — | — | |
| SCHEMBL11768749 | 0.85 | HDAC1 (0.93) | FOLH1KDM4EKDM6BKDM5CEGLN1 | |
| Glutarodihydroxamic Acid SCHEMBL11768782 | 0.85 | HDAC1 (0.81) | FOLH1KDM4EKDM6BKDM5CEGLN1 | |
| SCHEMBL27643837 | 0.84 | FOLH1 (0.57) | FOLH1KDM4EKDM6BKDM5CEGLN1 | |
| SCHEMBL137189 | 0.84 | — | — | |
| SCHEMBL4572119 | 0.84 | HDAC2 (0.57) | FOLH1KDM4EKDM6BKDM5CEGLN1 | |
| SCHEMBL8249763 | 0.84 | — | — | |
| SCHEMBL11769965 | 0.82 | HDAC1 (1.00) | FOLH1KDM4EKDM6BKDM5CEGLN1 | |
| Suberohydroxamic Acid SCHEMBL2159033 | 0.82 | HDAC1 (1.00) | FOLH1KDM4EKDM6BKDM5CEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117264598-B | Cobalt salt composite adhesive and preparation method thereof | 江阴市三良橡塑新材料有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-117264598-A | Cobalt salt composite adhesive and preparation method thereof | 江阴市三良橡塑新材料有限公司 | 2023-12-22 | — | — | CN | claimed |
| EP-2691454-B1 | CURABLE FLUOROELASTOMER COMPOSITION | DU PONT (US) | 2014-12-24 | — | — | EP | claimed |
| EP-2691454-A2 | CURABLE FLUOROELASTOMER COMPOSITION | E.I. Du Pont De Nemours And Company (US) | 2014-02-05 | — | — | EP | claimed |
| US-8618222-B2 | Curable fluoroelastomer composition | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-12-31 | — | — | US | claimed |
| US-20130066018-A1 | CURABLE FLUOROELASTOMER COMPOSTION | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-03-14 | — | — | US | claimed |
| WO-2012135780-A2 | CURABLE FLUOROELASTOMER COMPOSITION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-10-04 | — | — | WO | claimed |
| EP-1005449-B1 | 3-ARYL-SUCCINAMIDO-HYDROXAMIC ACIDS, METHODS FOR PRODUCING SAID ACIDS AND MEDICAMENTS CONTAINING THE SAME | ROCHE DIAGNOSTICS GMBH (DE) | 2002-10-30 | — | — | EP | claimed |
| EP-0944587-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-09-29 | — | — | EP | claimed |
| WO-1998024759-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-06-11 | — | — | WO | claimed |
| US-4939299-A | Succinyl dihydroxamic acids | MONSANTO COMPANY (US) | 1990-07-03 | — | — | US | claimed |
| EP-0271468-A2 | Gallium complexes and solvent extraction of gallium | Monsanto Company (US) | 1988-06-15 | — | — | EP | claimed |
| CN-117264598-B | Cobalt salt composite adhesive and preparation method thereof | 江阴市三良橡塑新材料有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11865195-B2 | Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| CN-117264598-A | Cobalt salt composite adhesive and preparation method thereof | 江阴市三良橡塑新材料有限公司 | 2023-12-22 | — | — | CN | disclosed |
| US-11653649-B2 | Antimicrobial composition including a dihydroxamic acid and methods of inhibiting microbial growth utilizing the same | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| EP-0811019-A1 | SYNTHESIS OF HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-12-10 | — | — | EP | disclosed |
| WO-1996026223-A1 | SYNTHESIS OF HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-08-29 | — | — | WO | disclosed |
| US-4939299-A | Succinyl dihydroxamic acids | MONSANTO COMPANY (US) | 1990-07-03 | — | — | US | disclosed |
| US-3979401-A | Polyfunctional aliphatic and cycloaliphatic cyclic nitrile sulfites and carbonates | ATLANTIC RICHFIELD COMPANY (US) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11653649-B2 | Antimicrobial composition including a dihydroxamic acid and methods of inhibiting microbial growth utilizing the same | DERA, DLD, DHODH | FOLH1 2014/4885KDM4E 4682/4885KDM6B 4138/4885 |
| US-11865195-B2 | Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging | MMP3, MMP1, TIMP3 | FOLH1 166/4885KDM4E 1930/4885KDM6B 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.